In the context of the cooperation in the fight against doping in sport, companies can use this template to undertake a review of project compounds (from candidate selection onward) to assess potential for risk for doping potential. This information will be reviewed internally for risk classification consisting of: A) no or negligible risk, B) possible...
Read moreCancer is one of the greatest health challenges of our time, and a leading cause of death in every corner of the world. Within the next two decades it is expected we reach 22 million new cases of cancer each year, the majority of them in low-and middle-income countries (LMICs). Without the preventative measures, the...
Read moreRead more
The Women’s Cancer Initiative in the Americas works to improve the quality and effectiveness of national breast and cervical cancer programs and the quality and completeness of national cancer registries in the region. The three-year partnership has reached its 1 year milestone and today launches its annual report to detail progress made in 2015. PAHO...
Read moreThis blog was originally posted on Devex. An estimated 400 million people do not have access to basic health care services. That’s about 1 in every 16 people who cannot visit a hospital or clinic to have their blood pressure measured, or learn how to properly care for their child with diabetes. Universal health coverage...
Read moreA must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What’s key is to increase the awareness of the potential impacts of the Nagoya Protocol on research and on our ability...
Read moreThe driving motivation of the pharmaceutical industry is to improve human health and well-being. Climate change will challenge the global community in its efforts to tackle health concerns and inequalities across the world. It can have consequences both for people living today, especially the poorest and most vulnerable, and for future generations. It is...
Read moreHave a quick look at our ‘pharma by numbers’ video illustrating the key 2015 facts & figures that range from innovation in R&D, to pharma & global health, and the pharma economic footprint. This video is based on the IFPMA yearly flagship publication http://ifpma.org
Read more